Shorter Dosing Schedule Maintains Efficacy in Refractory Colorectal Cancer Treatment, Trial Finds
A phase III clinical trial from Japan shows that a condensed 14-day cycle for refractory metastatic colorectal cancer treatment is as effective as the traditional 28-day schedule while lowering adverse side effects.
❤️Conditions & CarePhoto: medpagetoday.com
Key points
- The phase III PRABITAS trial evaluated 972 patients comparing a 14-day cycle against a standard 28-day cycle of FTD-TPI plus bevacizumab.
- Median overall survival was 10.3 months for the 28-day group and 11.3 months for the 14-day group, meeting noninferiority criteria.
- The shorter schedule significantly reduced the incidence of severe neutropenia and anorexia.
A shorter dosing schedule for a standard therapy combination used in treating refractory metastatic colorectal cancer preserves overall survival while reducing adverse side effects, according to findings from the phase III PRABITAS trial led by researchers in Japan and published in The Lancet.
The study evaluated 972 patients across 178 hospitals comparing the conventional 28-day regimen of trifluridine-tipiracil (FTD-TPI) combined with bevacizumab against a condensed 14-day schedule. Researchers observed a median overall survival of 10.3 months in the conventional group compared with 11.3 months in the shorter-schedule group, successfully meeting the study's threshold for noninferiority. Secondary measures, such as progression-free survival, were similar across both arms at 3.9 months.
Crucially, the 14-day schedule was linked to a lower burden of toxicities. Grade 3 or higher neutropenia dropped from 39% in the 28-day group to 13% in the shorter-course group, and occurrences of grade 2 or higher anorexia also declined. Accompanying editorialists noted that while the trial successfully demonstrated reduced toxicity and simplified administration, it did not formally assess whether these adjustments translated into measurable improvements in overall quality of life.
What to know: A condensed 14-day cycle for FTD-TPI plus bevacizumab appears noninferior in survival outcomes to the standard 28-day regimen while significantly decreasing certain hematologic and non-hematologic toxicities. Patients should consult their healthcare providers to discuss individualized treatment plans and the most appropriate care strategies.
Source medpagetoday.com — medpagetoday.com/hematologyoncology/coloncancer/123883 ↗
Read next
🏃FitnessUnderstanding and Addressing Love Handles Through Lifestyle Changes
Experts clarify that spot reduction of fat is not physiologically possible, recommending a combination of calorie management and high-intensity interval training instead.
🏃FitnessCiele Releases New Woolmark-Certified Merino Winter Running Apparel
Montreal-based brand Ciele has launched its second collection of merino wool running gear, featuring performance-focused fabrics designed for cold-weather training.
🏥Public HealthPreventive Services Task Force Resumes Meetings Under New Leadership
The U.S. Preventive Services Task Force is set to reconvene this week for the first time in over a year following a significant membership overhaul by Health Secretary Ro…
🧠AI AnalysisUltraprocessed Diets May Impact Brain Reward Systems in Younger Adults
A Virginia Tech study suggests that individuals aged 18 to 21 may experience changes in brain reward processing after consuming ultraprocessed foods, a response not obser…
🧠Mind & Mental HealthAddressing Body Image and the Reality of Gluteal Anatomy
A personal reflection on the social and psychological impact of body shape, specifically regarding the gluteal region, and the limitations of consumer solutions for perce…
🔬ResearchCBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities
A double-blind clinical trial published in JAMA Pediatrics indicates that CBD oil provides no significant behavioral improvement for children and teenagers with intellect…